Pharmacokinetic and clinical studies on cefodizime in the pediatric field

R. Fujii, O. Arimasu, H. Meguro, F. Hiruma, N. Sugie, T. Abe, S. Nakazawa, H. Sato, A. Narita, K. Matsumoto, H. Suzuki, S. Nakazawa, K. Niino, K. Sunakawa, Y. Sato, S. Iwata, H. Akita, N. Iwai, Y. Taneda

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A multi-center open study was conducted to investigate cefodizime (CDZM), a newly developed cephem antibiotic, from pharmacokinetic, bacteriological and clinical aspects, in the pediatric field with the participation of 17 institutions and their related facilities. The safety was evaluated in a total of 449 cases including 45 cases which were excluded from the clinical analysis because, to these cases, CDZM was not applicable. Side effects noted were diarrhea, loose stool, rash, itching, perleche, vascular pain etc., with most symptoms due to digestive tract disorders. Laboratory tests revealed abnormal values of S-GOT, S-GPT, eosinophil and platelet. These abnormal values were similar to those caused by other cephalosporin antibiotics in the severity. One each abnormal values for Al-P, direct bilirubin, LAP and γ-GTP were noted. However, these side effects and abnormalities in laboratory tests were not serious and all were normalized by discontinuation of the drug or even while the continuation of drug administration. From pharmacokinetic and clinical points of view, the usual dosage and administration recommendable is 20 mg/kg/dose of CDZM with a bolus intravenous injection or drip infusion, 3 times daily, by which a sufficient therapeutic effectiveness appears obtainable.

Original languageEnglish
Pages (from-to)1173-1193
Number of pages21
JournalJapanese Journal of Antibiotics
Volume42
Issue number5
Publication statusPublished - 1989
Externally publishedYes

Fingerprint

Intravenous Infusions
Pharmacokinetics
Pediatrics
Cephalosporins
Pruritus
Guanosine Triphosphate
Exanthema
Bilirubin
Eosinophils
Intravenous Injections
Pharmaceutical Preparations
Blood Vessels
Gastrointestinal Tract
Diarrhea
Blood Platelets
Anti-Bacterial Agents
Safety
Pain
cefodizime
Clinical Studies

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Fujii, R., Arimasu, O., Meguro, H., Hiruma, F., Sugie, N., Abe, T., ... Taneda, Y. (1989). Pharmacokinetic and clinical studies on cefodizime in the pediatric field. Japanese Journal of Antibiotics, 42(5), 1173-1193.

Pharmacokinetic and clinical studies on cefodizime in the pediatric field. / Fujii, R.; Arimasu, O.; Meguro, H.; Hiruma, F.; Sugie, N.; Abe, T.; Nakazawa, S.; Sato, H.; Narita, A.; Matsumoto, K.; Suzuki, H.; Nakazawa, S.; Niino, K.; Sunakawa, K.; Sato, Y.; Iwata, S.; Akita, H.; Iwai, N.; Taneda, Y.

In: Japanese Journal of Antibiotics, Vol. 42, No. 5, 1989, p. 1173-1193.

Research output: Contribution to journalArticle

Fujii, R, Arimasu, O, Meguro, H, Hiruma, F, Sugie, N, Abe, T, Nakazawa, S, Sato, H, Narita, A, Matsumoto, K, Suzuki, H, Nakazawa, S, Niino, K, Sunakawa, K, Sato, Y, Iwata, S, Akita, H, Iwai, N & Taneda, Y 1989, 'Pharmacokinetic and clinical studies on cefodizime in the pediatric field', Japanese Journal of Antibiotics, vol. 42, no. 5, pp. 1173-1193.
Fujii R, Arimasu O, Meguro H, Hiruma F, Sugie N, Abe T et al. Pharmacokinetic and clinical studies on cefodizime in the pediatric field. Japanese Journal of Antibiotics. 1989;42(5):1173-1193.
Fujii, R. ; Arimasu, O. ; Meguro, H. ; Hiruma, F. ; Sugie, N. ; Abe, T. ; Nakazawa, S. ; Sato, H. ; Narita, A. ; Matsumoto, K. ; Suzuki, H. ; Nakazawa, S. ; Niino, K. ; Sunakawa, K. ; Sato, Y. ; Iwata, S. ; Akita, H. ; Iwai, N. ; Taneda, Y. / Pharmacokinetic and clinical studies on cefodizime in the pediatric field. In: Japanese Journal of Antibiotics. 1989 ; Vol. 42, No. 5. pp. 1173-1193.
@article{046a5007fe274316911d59096340b596,
title = "Pharmacokinetic and clinical studies on cefodizime in the pediatric field",
abstract = "A multi-center open study was conducted to investigate cefodizime (CDZM), a newly developed cephem antibiotic, from pharmacokinetic, bacteriological and clinical aspects, in the pediatric field with the participation of 17 institutions and their related facilities. The safety was evaluated in a total of 449 cases including 45 cases which were excluded from the clinical analysis because, to these cases, CDZM was not applicable. Side effects noted were diarrhea, loose stool, rash, itching, perleche, vascular pain etc., with most symptoms due to digestive tract disorders. Laboratory tests revealed abnormal values of S-GOT, S-GPT, eosinophil and platelet. These abnormal values were similar to those caused by other cephalosporin antibiotics in the severity. One each abnormal values for Al-P, direct bilirubin, LAP and γ-GTP were noted. However, these side effects and abnormalities in laboratory tests were not serious and all were normalized by discontinuation of the drug or even while the continuation of drug administration. From pharmacokinetic and clinical points of view, the usual dosage and administration recommendable is 20 mg/kg/dose of CDZM with a bolus intravenous injection or drip infusion, 3 times daily, by which a sufficient therapeutic effectiveness appears obtainable.",
author = "R. Fujii and O. Arimasu and H. Meguro and F. Hiruma and N. Sugie and T. Abe and S. Nakazawa and H. Sato and A. Narita and K. Matsumoto and H. Suzuki and S. Nakazawa and K. Niino and K. Sunakawa and Y. Sato and S. Iwata and H. Akita and N. Iwai and Y. Taneda",
year = "1989",
language = "English",
volume = "42",
pages = "1173--1193",
journal = "The Journal of antibiotics. Ser. B",
issn = "0368-2781",
publisher = "Japan Antibiotics Research Association",
number = "5",

}

TY - JOUR

T1 - Pharmacokinetic and clinical studies on cefodizime in the pediatric field

AU - Fujii, R.

AU - Arimasu, O.

AU - Meguro, H.

AU - Hiruma, F.

AU - Sugie, N.

AU - Abe, T.

AU - Nakazawa, S.

AU - Sato, H.

AU - Narita, A.

AU - Matsumoto, K.

AU - Suzuki, H.

AU - Nakazawa, S.

AU - Niino, K.

AU - Sunakawa, K.

AU - Sato, Y.

AU - Iwata, S.

AU - Akita, H.

AU - Iwai, N.

AU - Taneda, Y.

PY - 1989

Y1 - 1989

N2 - A multi-center open study was conducted to investigate cefodizime (CDZM), a newly developed cephem antibiotic, from pharmacokinetic, bacteriological and clinical aspects, in the pediatric field with the participation of 17 institutions and their related facilities. The safety was evaluated in a total of 449 cases including 45 cases which were excluded from the clinical analysis because, to these cases, CDZM was not applicable. Side effects noted were diarrhea, loose stool, rash, itching, perleche, vascular pain etc., with most symptoms due to digestive tract disorders. Laboratory tests revealed abnormal values of S-GOT, S-GPT, eosinophil and platelet. These abnormal values were similar to those caused by other cephalosporin antibiotics in the severity. One each abnormal values for Al-P, direct bilirubin, LAP and γ-GTP were noted. However, these side effects and abnormalities in laboratory tests were not serious and all were normalized by discontinuation of the drug or even while the continuation of drug administration. From pharmacokinetic and clinical points of view, the usual dosage and administration recommendable is 20 mg/kg/dose of CDZM with a bolus intravenous injection or drip infusion, 3 times daily, by which a sufficient therapeutic effectiveness appears obtainable.

AB - A multi-center open study was conducted to investigate cefodizime (CDZM), a newly developed cephem antibiotic, from pharmacokinetic, bacteriological and clinical aspects, in the pediatric field with the participation of 17 institutions and their related facilities. The safety was evaluated in a total of 449 cases including 45 cases which were excluded from the clinical analysis because, to these cases, CDZM was not applicable. Side effects noted were diarrhea, loose stool, rash, itching, perleche, vascular pain etc., with most symptoms due to digestive tract disorders. Laboratory tests revealed abnormal values of S-GOT, S-GPT, eosinophil and platelet. These abnormal values were similar to those caused by other cephalosporin antibiotics in the severity. One each abnormal values for Al-P, direct bilirubin, LAP and γ-GTP were noted. However, these side effects and abnormalities in laboratory tests were not serious and all were normalized by discontinuation of the drug or even while the continuation of drug administration. From pharmacokinetic and clinical points of view, the usual dosage and administration recommendable is 20 mg/kg/dose of CDZM with a bolus intravenous injection or drip infusion, 3 times daily, by which a sufficient therapeutic effectiveness appears obtainable.

UR - http://www.scopus.com/inward/record.url?scp=0024371563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024371563&partnerID=8YFLogxK

M3 - Article

C2 - 2664256

AN - SCOPUS:0024371563

VL - 42

SP - 1173

EP - 1193

JO - The Journal of antibiotics. Ser. B

JF - The Journal of antibiotics. Ser. B

SN - 0368-2781

IS - 5

ER -